KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 32.75% to $25.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $91.6 million, a 13.86% increase, with the full-year FY2025 number at $91.6 million, up 13.86% from a year prior.
  • Depreciation & Amortization (CF) was $25.0 million for Q4 2025 at Supernus Pharmaceuticals, up from $24.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $25.0 million in Q4 2025 to a low of $6.6 million in Q1 2021.
  • A 5-year average of $18.7 million and a median of $20.7 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 280.6% in 2021; the steepest drop was 14.89% in 2021.
  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) stood at $12.7 million in 2021, then skyrocketed by 64.07% to $20.8 million in 2022, then increased by 3.97% to $21.7 million in 2023, then decreased by 13.06% to $18.8 million in 2024, then skyrocketed by 32.75% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Depreciation & Amortization (CF) are $25.0 million (Q4 2025), $24.8 million (Q3 2025), and $21.4 million (Q2 2025).